Quince Therapeutics Inc., a biotechnology company focused on treating rare diseases, has announced a private placement of securities expected to generate approximately $11.5 million in upfront proceeds. The financing, led by Nantahala Capital and involving existing stockholders like ADAR1 Capital Management and Quince's senior management, could potentially raise an additional $10.4 million if the accompanying warrants are fully exercised. Priced at a premium to the last close, the funds are intended for working capital, general corporate purposes, and to support the ongoing Phase 3 NEAT clinical trial in Ataxia-Telangiectasia. Combined with existing resources, this financing is expected to support Quince's operations until mid-2026 or beyond, depending on warrant exercise.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。